

03-06-07

18W/BS



PTO/SB/21 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h1>TRANSMITTAL FORM</h1> <p><i>(to be used for all correspondence after initial filing)</i></p>		Application Number	10/608,723-Conf. #6915
		Filing Date	June 26, 2003
		First Named Inventor	Andrew R. MARKS
		Art Unit	1646
		Examiner Name	R. Li
Total Number of Pages in This Submission		Attorney Docket Number	0019240.00594US1

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard Form SB08 Certificate of Express Mailing
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	WILMER CUTLER PICKERING HALE AND DORR LLP		
Signature	<i>Jane M. Love</i>		
Printed name	Jane M. Love, Ph.D.		
Date	3/5/07	Reg. No.	42,812

Express Mail Label No. EV 901256293 US Dated: 3/5/07

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). FEE TRANSMITTAL For FY 2006		Complete if Known Application Number 10/608,723-Conf. #6915 Filing Date June 26, 2003 First Named Inventor Andrew R. MARKS Examiner Name R. Li Art Unit 1646 Attorney Docket No. 0019240.00594US1	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27			
TOTAL AMOUNT OF PAYMENT (\$) 180.00			

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____
☒ Deposit Account Deposit Account Number: 08-0219 Deposit Account Name: Wilmer Cutler Pickering Hale and Dorr LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee
☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

Total Claims Extra Claims Fee (\$) Fee Paid (\$) Multiple Dependent Claims
 _____ = _____ x _____ = _____
 Fee (\$) Fee Paid (\$)

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims Extra Claims Fee (\$) Fee Paid (\$)

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$) Fee Paid (\$)

_____ - 100 = _____ / 50 _____ (round up to a whole number) x _____ = _____

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement 180.00

SUBMITTED BY

Signature	<i>Jane M. Love</i>	Registration No. (Attorney/Agent)	42,812	Telephone	(212) 230-8800
Name (Print/Type)	Jane M. Love, Ph.D.	Date	3/5/07		

Express Mail Label No. EV 901256293 US Dated: 3/5/07

Express Mail Label No. EV 901256293 US

Dated:

3/5/07

Docket No.: 0019240.00594US1
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andrew R. Marks Confirmation No.: 6915
Application No.: 10/608,723 Art Unit: 1646
Filed: June 26, 2003 Examiner: R. Li
Title: METHODS FOR TREATING AND PREVENTING CARDIAC
ARRHYTHMIA

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicant brings to the attention of the Examiner the documents listed on the attached Form PTO SB-08. Copies of the documents listed are not submitted herewith. These documents were previously cited by or submitted to the United States Patent and Trademark Office in U.S. Patent Application No. 10/288,606, filed November 5, 2002 and is relied upon in this application for an earlier filing date under 35 U.S.C. 120.

This Information Disclosure Statement is being filed after the mailing date of the final Office Action on the merits and before the mailing date of a Notice of Allowance.

Please charge the \$180.00 fee to our Deposit account 08-0219.

03/07/2007 DEMMANU1 00000048 080219 10608723


01 FC:1806 180.00 DA

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Dated:

3/5/07

Respectfully submitted,



Jane M. Love, Ph.D.
Registration No.: 42,812
Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP
399 Park Avenue
New York, New York 10022
(212) 230-8800 (telephone)
(212) 230-8888 (facsimile)



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/608,723-Conf. #6915		
		Filing Date	June 26, 2003		
		First Named Inventor	Andrew R. MARKS		
		Art Unit	1646		
		Examiner Name	R. Li		
Sheet	1	of	9	Attorney Docket Number	0019240.00594US1

U.S. PATENT DOCUMENTS						
Examiner. Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code ² (if known)				
	AA*	US-4,567,254	01-28-1986	Kataoka et al.		
	AB*	US-4,658,055	04-14-1987	Onuki et al.		
	AC*	US-4,723,012	02-02-1988	Matsumoto et al.		
	AD*	US-4,841,055	06-20-1989	Matsumoto et al.		
	AE*	US-4,845,065	07-04-1989	Sugimori et al.		
	AF*	US-4,849,535	07-18-1989	Naora et al.		
	AG*	US-4,888,418	12-19-1989	Kawai et al.		
	AH*	US-5,142,647	08-25-1992	Nakagawa et al.		
	AI*	US-5,153,184	10-06-1992	Reifschneider et al.		
	AJ*	US-5,166,347	11-24-1992	Izawa et al.		
	AK*	US-5,179,125	01-12-1993	Mimura et al.		
	AL*	US-5,204,462	04-20-1993	Kobayashi et al.		
	AM*	US-5,210,266	05-11-1993	Mimura et al.		
	AN*	US-5,214,056	05-25-1993	Haruta et al.		
	AO*	US-5,223,508	06-29-1993	Izawa et al.		
	AP*	US-5,260,286	11-09-1993	Lawson et al.		
	AQ*	US-5,272,164	12-21-1993	Izawa et al.		
	AR*	US-5,304,380	04-19-1994	Miyajima et al.		
	AS*	US-5,304,558	04-19-1994	Kaneko et al.		
	AT*	US-5,332,734	07-26-1994	Kobayashi et al.		
	AU*	US-5,354,758	10-11-1994	Lawson et al.		
	AV*	US-5,387,684	02-07-1995	Inoue et al.		
	AW*	US-5,413,929	05-09-1995	Ishizaki et al.		
	AX*	US-5,453,282	09-26-1995	Kanauchi et al.		
	AY*	US-5,457,182	10-10-1995	Wiederrecht et al.		
	AZ*	US-5,476,780	12-19-1995	Watanabe et al.		
	AA1*	US-5,478,832	12-26-1995	Inoue et al.		
	AB1*	US-5,508,293	04-16-1996	Okawara et al.		
	AC1*	US-5,523,410	06-04-1996	Kagara et al.		
	AD1*	US-5,593,988	01-14-1997	Tahara et al.		
	AE1*	US-5,624,961	04-29-1997	Ban et al.		
	AF1*	US-5,654,001	08-05-1997	Kanauchi et al.		
	AG1*	US-5,665,881	09-09-1997	Inoue et al.		
	AH1*	US-5,719,155	02-17-1998	Cho et al.		
	AI1*	US-5,750,696	05-12-1998	Shibata et al.		
	AJ1*	US-5,753,649	05-19-1998	Tahara et al.		
	AK1*	US-5,767,247	06-16-1998	Kaneko et al.		
	AL1*	US-5,780,441	07-14-1998	Higa et al.		
	AM1*	US-5,792,655	08-11-1998	Watanabe et al.		
	AN1*	US-5,807,850	09-15-1998	Nakamura et al.		
	AO1*	US-5,824,862	10-20-1998	Hiyoshi et al.		
	AP1*	US-5,906,819	05-25-1999	Kaibuchi et al.		
	AQ1*	US-6,013,499	01-11-2000	Narumiya et al.		
	AR1*	US-6,111,072	08-29-2000	Narumiya et al.		
	AS1*	US-6,130,060	10-10-2000	Nakamura, deceased et al.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

6089885

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/608,723-Conf. #6915
				Filing Date	June 26, 2003
				First Named Inventor	Andrew R. MARKS
				Art Unit	1646
				Examiner Name	R. Li
Sheet	2	of	9	Attorney Docket Number	0019240.00594US1

	AT1*	US-6,184,352	02-06-2001	Nakamura et al.	
	AU1*	US-6,235,730	05-22-2001	Sato et al.	
	AV1*	US-6,255,472	07-03-2001	Tokino et al.	
	AW1*	US-6,271,353	08-07-2001	Nakamura et al.	
	AX1*	US-6,313,113	11-06-2001	Lohray et al.	
	AY1*	US-6,316,485	11-13-2001	Nakamura et al.	
	AZ1*	US-6,338,955-A1	01-15-2002	Oguri et al.	
	AA2*	US-6,348,334	02-19-2002	Nagata et al.	
	AB2*	US-6,362,231	03-26-2002	Sakai et al.	
	AC2*	US-2002/0042405-A1	04-11-2002	Schuh	
	AD2*	US-20020052358-A1	05-02-2002	Chubinskaya et al.	
	AE2*	US-6,391,595	05-21-2002	Kato et al.	
	AF2*	US-6,403,830-A1	06-11-2002	Webber et al.	
	AG2*	US-6,410,561	06-25-2002	Shinkai et al.	
	AH2*	US-6,426,365	07-30-2002	Shinkai et al.	
	AI2*	US-20020107406-A1	08-08-2002	Sakai et al.	
	AJ2*	US-20020115831-A1	08-22-2002	Tamatani et al.	
	AK2*	US-20020132001-A1	09-19-2002	Garthwaite et al.	
	AL2*	US-6,465,518-A1	10-15-2002	Hansen, Jr. et al.	
	AM2*	US-6,465,686-A1	10-15-2002	Grappenhau et al.	
	AN2*	US-20020151685-A1	10-17-2002	Tamatani et al.	
	AO2*	US-20020156242-A1	10-24-2002	Tamatani et al.	
	AP2*	US-6,495,544-A1	12-17-2002	Hansen, Jr. et al.	
	AQ2*	US-20020199213-A1	12-26-2002	Tomizuka et al.	
	AR2*	US-6,500,816	12-31-2002	Ekimoto et al.	
	AS2*	US-20030044845-A1	03-06-2003	Jenkins et al.	
	AT2*	US-20030055027-A1	03-20-2003	Schun	
	AU2*	US-20030055087-A1	03-20-2003	Shinkai et al.	
	AV2*	US-20030064406-A1	04-03-2003	Kaneko et al.	
	AW2*	US-6,545,170-A1	04-08-2003	Pitzele et al.	
	AX2*	US-20030083472-A1	05-01-2003	Tamatani et al.	
	AY2*	US-20030087907-A1	05-08-2003	Kubo et al.	
	AZ2*	US-20030092708-A1	05-15-2003	Shinkai et al.	
	AA3*	US-6,562,618	05-13-2003	Tamatani et al.	
	AB3*	US-6,562,828	05-13-2003	Katoh et al.	
	AC3*	US-6,583,157-A1	06-24-2003	McGee et al.	
	AD3*	US-6,586,474-A1	07-01-2003	Webber et al.	
	AE3*	US-20030124637-A1	07-03-2003	Kaneko et al.	
	AF3*	US-20030144526-A1	07-31-2003	Sakai et al.	
	AG3*	US-20030176485-A1	09-18-2003	Sakai et al.	
	AH3*	US-20030181764-A1	09-25-2003	Ikawa et al.	
	AI3*	US-20030186885-A1	10-02-2003	Tandon et al.	
	AJ3*	US-20030191323-A1	10-09-2003	Ikawa et al.	
	AK3*	US-6,632,976	10-14-2003	Tomizuka et al.	
	AL3*	US-20030195218-A1	10-16-2003	Koeller et al.	
	AM3*	US-20030199482-A1	10-23-2003	Seibert et al.	
	AN3*	US-20030199701-A1	10-23-2003	Webber et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/608,723-Conf. #6915	
			Filing Date	June 26, 2003	
			First Named Inventor	Andrew R. MARKS	
			Art Unit	1646	
			Examiner Name	R. Li	
Sheet	3	of	9	Attorney Docket Number	0019240.00594US1

AO3*	US-20030220310-A1	11-27-2003	Schuh	
AP3*	US-20030220312-A1	11-27-2003	Schuh	
AQ3*	US-6,660,837	12-09-2003	Kaibuchi et al.	
AR3*	US-20030232855-A1	12-18-2003	Iwamura et al.	
AS3*	US-6,649,366-A1	11-18-2003	Chubinskaya et al.	
AT3*	US-20040006099-A1	01-08-2004	Kato et al.	
AU3*	US-20040017409-A1	01-29-2004	Mizutani et al.	
AV3*	US-6,673,904-A1	01-06-2004	Nishikawa et al.	
AW3*	US-6,683,083	01-27-2004	Kaneko et al.	
AX3*	US-20040053919-A1	03-18-2004	Chubinskaya et al.	
AY3*	US-20040073012-A1	04-15-2004	Tamatani et al.	
AZ3*	US-20040073957-A1	04-15-2004	Tomizuka et al.	
AA4*	US-6,750,255-A1	06-15-2004	Sakai et al.	
AB4*	US-6,753,346-A1	06-22-2004	Shinkai et al.	
AC4*	US-20040120945-A1	06-24-2004	Tamatani et al.	
AD4*	US-6,756,406-A1	06-29-2004	Durley et al.	
AE4*	US-20040132658-A1	07-08-2004	Tamatani et al.	
AF4*	US-20040132727-A1	07-08-2004	Sakai et al.	
AG4*	US-20040146506-A1	07-29-2004	Tamatani et al.	
AH4*	US-20040146991-A1	07-29-2004	Tsuji et al.	
AI4*	US-20040151669-A1	08-05-2004	Tamatani et al.	
AJ4*	US-20040151718-A1	08-05-2004	Tamatani et al.	
AK4*	US-20040151720-A1	08-05-2004	Tamatani et al.	
AL4*	US-20040171613-A1	09-02-2004	Iwamura et al.	
AM4*	US-6,787,668-A1	09-07-2004	Pitzele et al.	
AN4*	US-20040175814-A1	09-09-2004	Kato et al.	
AO4*	US-20040180052-A1	09-16-2004	Tsuji et al.	
AP4*	US-20040186178-A1	09-23-2004	Webber et al.	
AQ4*	US-20040192584-A1	09-30-2004	McMahon et al.	
AR4*	US-20040198719-A1	10-07-2004	Laborde et al.	
AS4*	US-6,803,039-A1	10-12-2004	Tsuji et al.	
AT4*	US-20040209871-A1	10-21-2004	Fox et al.	
AU4*	US-6,812,252-A1	11-02-2004	Ikawa et al.	
AV4*	US-20040220193-A1	11-04-2004	Yamamoto et al.	
AW4*	US-20040225018-A1	11-11-2004	Sunami et al.	
AX4*	US-20040229788-A1	11-18-2004	Tamatani et al.	
AY4*	US-20040229790-A1	11-18-2004	Tezuka et al.	
AZ4*	US-20040229803-A1	11-18-2004	Stephenson et al.	
AA5*	US-20040229876-A1	11-18-2004	Kubo et al.	
AB5*	US-20040229957-A1	11-18-2004	Shinkai et al.	
AC5*	US-6,821,987-A1	11-23-2004	Kubo et al.	
AD5*	US-20040235162-A1	11-25-2004	Sato	
AE5*	US-6,824,973-A1	11-30-2004	Tang et al.	
AF5*	US-20040242683-A1	12-02-2004	Urata et al.	
AG5*	US-6,828,456-A1	12-07-2004	Hansen, Jr. et al.	
AH5*	US-6,830,896-A1	12-14-2004	Kaneko et al.	
AI5*	US-20050009733-A1	01-13-2005	Stephenson et al.	

Examiner Signature	Date Considered
-----------------------	--------------------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/608,723-Conf. #6915
				Filing Date	June 26, 2003
				First Named Inventor	Andrew R. MARKS
				Art Unit	1646
				Examiner Name	R. Li
Sheet	4	of	9	Attorney Docket Number	0019240.00594US1

	AJ5*	US-20050020668-A1	01-27-2005	Urata et al.	
	AK5*	US-6,852,753-A1	02-08-2005	Koeller et al.	
	AL5*	US-20050032210-A1	02-10-2005	Sato et al.	
	AM5*	US-20050035939-A1	02-17-2005	Akiyama	
	AN5*	US-20050051181-A1	03-10-2005	Okamoto	
	AO5*	US-20050059655-A1	03-17-2005	Garvey et al.	
	AP5*	US-20050059810-A1	03-17-2005	Maeda et al.	
	AQ5*	US-6,869,975-A1	03-22-2005	Abe et al.	
	AR5*	US-20050070543-A1	03-31-2005	Stephenson	
	AS5*	US-20050070545-A1	03-31-2005	Fox et al.	
	AT5*	US-20050074762-A1	04-07-2005	Nakamura et al.	
	AU5*	US-6,890,531	05-10-2005	Horie et al.	
	AV5*	US-6,897,295	05-24-2005	Nagata et al.	
	AW5*	US-20050113451-A1	05-26-2005	Hansen et al.	
	AX5*	US-6,906,072	06-14-2005	Yamamoto et al.	
	AY5*	US-6,914,158-A1	07-05-2005	Webber et al.	
	AZ5*	US-20050159365-A1	07-21-2005	Serizawa et al.	
	AA6*	US-20050159403-A1	07-21-2005	Stephenson et al.	
	AB6*	US-20050165106-A1	07-28-2005	Webber et al.	
	AC6*	US-20050171196-A1	08-04-2005	Fujii et al.	
	AD6*	US-20050177884-A1	08-11-2005	Tomizuka et al.	
	AE6*	US-20050187221-A1	08-25-2005	Matsuda et al.	
	AF6*	US-20050192259-A1	09-01-2005	Garthwaite et al.	
	AG6*	US-6,939,895-A1	09-06-2005	Sakai et al.	
	AH6*	US-20050213426-A1	09-29-2005	Midas et al.	
	AI6*	US-6,951,889-A1	10-04-2005	Hansen, Jr. et al.	
	AJ6*	US-6,962,926-A1	11-08-2005	Laborde et al.	
	AK6*	US-6,964,975-A1	11-15-2005	Ueno et al.	
	AL6*	US-20050255546-A1	11-17-2005	Nishikawa	
	AM6*	US-20050256199-A1	11-17-2005	Durley et al.	
	AN6*	US-20050277649-A1	12-15-2005	DeGraffenreid et al.	
	AO6*	US-6,977,252	12-20-2005	Kaneko et al.	
	AP6*	US-20060011375-A1	01-19-2006	Sugimoto et al.	
	AQ6*	US-20060014768-A1	01-19-2006	Kawasaki et al.	
	AR6*	US-20060026698-A1	02-02-2006	Tomizuka et al.	
	AS6*	US-20060030565-A1	02-09-2006	Shinkai et al.	
	AT6*	US-6,998,469-A1	02-14-2006	Tandon et al.	
	AU6*	US-20060035882-A1	02-16-2006	Koga et al.	
	AV6*	US-20060037093-A1	02-16-2006	Tomizuka et al.	
	AW6*	US-20060041945-A1	02-23-2006	Robl et al.	
	AX6*	US-7,005,450-A1	02-28-2006	Durley et al.	
	AY6*	US-20060059575-A1	03-16-2006	Kusunoki et al.	
	AZ6*	US-20060078992-A1	04-13-2006	Misawa et al.	
	AA7*	US-7,029,671	04-18-2006	Koezuka et al.	
	AB7*	US-7,030,225	04-18-2006	Tamatani et al.	
	AC7*	US-20060084658-A1	04-20-2006	Yamamoto et al.	
	AD7*	US-7,041,870-A1	05-09-2006	Tomizuka et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/608,723-Conf. #6915	
			Filing Date	June 26, 2003	
			First Named Inventor	Andrew R. MARKS	
			Art Unit	1646	
			Examiner Name	R. Li	
Sheet	5	of	9	Attorney Docket Number	0019240.00594US1

AE7*	US-7,045,615-A1	05-16-2006	Tamatani et al.	
AF7*	US-20060122181-A1	06-08-2006	Ikemoto et al.	
AG7*	US-20060123490-A1	06-08-2006	Kakitani et al.	
AH7*	US-7,064,194-A1	06-20-2006	Misawa et al.	
AI7*	US-20060135506-A1	06-22-2006	Stephenson et al.	
AJ7*	US-20060167043-A1	07-27-2006	Iwakubo et al.	
AK7*	US-20060185025-A1	08-17-2006	Oshimura et al.	
AL7*	US-20060189603-A1	08-24-2006	Garvey et al.	
AM7*	US-7,102,013-A1	09-05-2006	Webber et al.	
AN7*	US-20060205731-A1	09-14-2006	Kodama et al.	
AO7*	US-20060211717-A1	09-21-2006	Sakai et al.	
AP7*	US-7,112,655	09-26-2006	Tamatani et al.	
AQ7*	US-20060217426-A1	09-28-2006	Eto et al.	
AR7*	US-20060223133-A1	10-05-2006	Tamatani et al.	
AS7*	US-20060233902-A1	10-19-2006	Yajima et al.	
AT7*	US-7,135,466-A1	11-14-2006	Sakai et al.	
AU7*	US-20060258701-A1	11-16-2006	Mitsuya et al.	
AV7*	US-20060270705-A1	11-30-2006	Yonemori et al.	
AW7*	US-20070010571-A1	01-11-2007	Garvey et al.	
AX7*	US-20070010670-A1	01-11-2007	Hirata et al.	
AY7*	US-7,163,952-A1	01-16-2007	Inaba et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	BA	EP-0467325	01-22-1992	Syntex (USA) Inc.		
	BB	WO-98/45291	10-15-1998	Dr. Reddy's Research Foundation		
	BC	WO-99/16758	04-08-1999	Dr. Reddy's Research Foundation		
	BD	WO-05/105793	11-10-2005	Aetas Pharma Co. Ltd		
	BE	EP-1743895	01-17-2007	Aetas Pharma Col., Ltd.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Ackerman, MJ, "Cardiac channelopathies: it's in the genes," Nat. Med., Vol. 10, pp. 463-4 (2004)	
	CB	Bangur, et al., "Mutational analysis of the D1/E1 core helices and the conserved N-terminal region of yeast transcription factor IIB (TFIIB): identification of an N-terminal mutant that	
Examiner Signature			Date Considered

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/608,723-Conf. #6915
				Filing Date	June 26, 2003
				First Named Inventor	Andrew R. MARKS
				Art Unit	1646
				Examiner Name	R. Li
Sheet	6	of	9	Attorney Docket Number	0019240.00594US1

		stabilizes TATA-binding protein-TFII-B-DNA complexes," Mol. Cell Biol., Vol. 17, pp. 6784-93 (1997)	
	CC	Behr, et al., "Cardiological assessment of first-degree relatives in sudden arrhythmic death syndrome," The Lancet, Vol. 362, 1457-59 (2003)	
	CD	Brillantes, et al., "Developmental and tissue-specific regulation of rabbit skeletal and cardiac muscle calcium channels involved in excitation-contraction coupling," Circ. Res., Vol. 75, pp. 503-10 (1994)	
	CE	Brillantes, et al., "Differences in cardiac calcium release channel (ryanodine receptor) expression in myocardium from patients with end-stage heart failure caused by ischemic versus dilated cardiomyopathy," Circ. Res., Vol. 71, pp. 18-26 (1992)	
	CF	Chatrath, et al., "Beta-blocker therapy failures in symptomatic probands with genotyped long-QT syndrome," Pediatr. Cardiol., Vol. 25, pp. 459-65 (2004)	
	CG	Che, et al., "Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazepine derivative, JTV-519," Cancer Lett., Vol. 187, pp. 111-9 (2002)	
	CH	Choi, et al., "Spectrum and frequency of cardiac channel defects in swimming-triggered arrhythmia syndromes," Circulation, Vol. 110, pp. 2119-24 (2004)	
	CI	Choi, et al., "Sudden cardiac death and channelopathies: a review of implantable defibrillator therapy," Pediatr. Clin. North Am., Vol. 51, pp. 1289-1303 (2004)	
	CJ	Culligan, et al., "Drastic reduction of calsequestrin-like proteins and impaired calcium binding in dystrophic mdx muscle," J. Appl. Physiol., Vol. 92, pp. 435-445 (2002)	
	CK	Doi et al., "Propranolol prevents the Development of Heart Failure by Restoring FKBP12.60-Mediated Stabilization of Ryanodine Receptor," Circulation Vol. 105, pp. 1374-1379. (2002).	
	CL	Dorian, P., "Antiarrhythmic action of beta-blockers: potential mechanisms," J. Cardiovasc. Pharmacol. Therapeut., Vol. 10, pp. S15-S22 (2005)	
	CM	Echt et al., "Mortality and morbidity in patients receiving encainide, flecainide, or placebo," The Cardiac Arrhythmia Suppression Trial, N. Engl. J. Med., Vol 324, pp. 781-788. (1991)	
	CN	Farr, et al., "Sparking the failing heart," N. Engl. J. Med., Vol. 351, pp. 185-7 (2004)	
	CO	Fitzgerald, et al., "Reduced ryanodine receptor content in isolated neonatal cardiomyocytes compared with the intact tissue," J. Mol. Cell. Cardiol., Vol. 26, pp. 1261-5 (1994)	
	CP	Gillian, et al., "Analysis of expression of the human ryanodine receptor gene in malignant hyperthermia skeletal muscle tissue," Biochem. Soc. Trans., Vol. 19, pp. 46S (1991)	
	CQ	Haut, Donahue, et al., "Annexin V Disruption Impairs Mechanically Induced Calcium Signaling in Osteoblastic Cells," Bone, Vol 35, No 3 pp. 656-63, (2004)	
	CR	Ikemoto, et al., "Regulation of calcium release by interdomain interaction within ryanodine receptors," Front Biosci., Vol. 7, pp. d671-683 (2002)	
	CS	Ishii, et al., "JTV-519, a new cardioprotective drug, and cariporide, synergistically improved post-ischemic contractile recovery in rat," Journal of Molecular and Cellular Cardiology, Vol. 35, Issue 6, p A29 (2002)	
	CT	Kirsch, et al., "The roles of annexins and types II and X collagen in matrix vesicle-mediated mineralization of growth plate cartilage," J. Biol. Chem., Vol. 275, pp. 35577-83 (2000)	
	CU	Kobrinisky, et al., "Expressed ryanodine receptor can substitute for the inositol 1,4,5-trisphosphate receptor in Xenopus laevis oocytes during progesterone-induced maturation," Dev. Biol., Vol. 172, pp. 531-40 (1995)	
	CV	Lee, et al., "Sudden unexplained death: evaluation of those left behind," The Lancet, Vol. 362, pp. 1429-1431 (2003)	
	CW	Lehnart, et al., "Calstabin deficiency, ryanodine receptors, and sudden cardiac death," Biochem. Biophys. Res. Commun., Vol. 322, pp. 1267-79 (2004)	
	CX	Lehnart, et al., "Immunophilins and coupled gating of ryanodine receptors," Curr. Top. Med.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/608,723-Conf. #6915		
		Filing Date	June 26, 2003		
		First Named Inventor	Andrew R. MARKS		
		Art Unit	1646		
		Examiner Name	R. Li		
Sheet	7	of	9	Attorney Docket Number	0019240.00594US1

		Chem., Vol. 3, pp. 1383-91 (2003)	
	CY	Lesh, et al., "Anti-ryanodine receptor antibody binding sites in vascular and endocardial endothelium," Cir., Res., Vol. 72, pp. 481-8 (1993)	
	CZ	Manzur, et al., "A severe clinical and pathological variant of central core disease with possible autosomal recessive inheritance," Neur. Disorders, Vol. 8, pp. 467-473 (1998)	
	CA1	Marks, AR, "Arrhythmias of the heart: beyond ion channels," Nat. Medicine, Vol. 9, pp. 263-4, (2003)	
	CB1	Marks, AR, "Calcium and the heart: a question of life and death," J. Clin. Investigation, Vol. 111, pp. 597-600, (2003)	
	CC1	Marks, AR, "Calcium channels expressed in vascular smooth muscle," Circulation, Vol. 86, pp. III61-7 (1992)	
	CD1	Marks, AR, "Immunophilin modulation of calcium channel gating," Methods., Vol. 9, pp. 177-87 (1996)	
	CE1	Marks, AR, "Intracellular calcium-release channels: regulators of cell life and death," Am. J. Physiol., Vol. 272, pp. H597-605 (1997)	
	CF1	Marks, et al., "Molecular cloning and characterization of the Ryanodine receptor/junctional channel complex cDNA from skeletal muscle sarcoplasmic reticulum," Proc. Natl. Acad. Sci. U.S.A., Vol. 86, pp. 8683-7 (1989)	
	CG1	Marks, et al., "Regulation of ryanodine receptors via macromolecular complexes: a novel role for leucine/isoleucine zippers," Trends Cardiovasc. Med., Vol. 12, pp. 166-70 (2002)	
	CH1	Marks, et al., "Surface topography analysis of the ryanodine receptor/junctional channel complex based on proteolysis sensitivity mapping," J. Biol. Chem., Vol. 265, pp. 13143-9 (1990)	
	CI1	Marks, et al., "The ryanodine receptor/junctional channel complex is regulated by growth factors in a myogenic cell line," J. Cell. Biol., Vol. 114, pp. 303-12, (1991)	
	CJ1	Maron, et al., "Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases," Circulation, Vol., 109, pp. 2807-16 (2004)	
	CK1	Marx et al. "Requirement of a Macromolecular signaling complex for Beta-Adrenergic Receptor Modulation of the KCNQ1/KCNE1 Potassium Channel," Science, Vol. 295, pp. 496-499. (2002).	
	CL1	McPhie, et al., "Structure of the hormone binding domain of human beta 1 thyroid hormone nuclear receptor: is is an alpha/beta barrel?" Biochemistry, Vol. 32, pp. 7460-5 (1993)	
	CM1	Morita, et al., "Ca channel blocking activity of JTV-519, a novel protective drug to cytotoxicity," Neuroscience Research, Vol. 31, Supp. 1, p. S65 (1998)	
	CN1	Nakamura, et al., "Reversal of cisplatin resistance by the 1,4-benzothiazepine derivative, JTV-519," Jpn. J. Cancer Res., Vol. 92, pp. 597-602 (2001)	
	CO1	Nakaya et al. "Inhibitory Effects of JTV-519, a Novel Cardioprotective Drug, on Potassium Currents and Experimental Atrial Fibrillation in Guinea-Pig Hearts," British Journal of Pharmacology, Vol. 131, pp. 1363-1372. (2000).	
	CP1	Ondrias, et al., "FKBP12 modulates gating of the ryanodine receptor/calcium release channel," Ann. N.Y. Acad. Sci., Vol. 853, pp. 149-56 (1998)	
	CQ1	Ondrias, et al., "Single channel properties and calcium conductance of the cloned expressed ryanodine receptor/calcium-release channel, Soc. Gen. Physiol. Serv., Vol. 51, pp. 29-45 (1996)	
	CR1	Paul-Pletzer, et al., "Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor," J. Biol. Chem., Vol. 277, pp. 34918-23 (2002)	
	CS1	Roseblit, et al., "Intracellular calcium release channel expression during embryogenesis."	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/608,723-Conf. #6915
				Filing Date	June 26, 2003
				First Named Inventor	Andrew R. MARKS
				Art Unit	1646
				Examiner Name	R. Li
Sheet	8	of	9	Attorney Docket Number	0019240.00594US1

		Dev. Biol., Vol. 206, pp. 163-77 (1999)	
CT1	Schotten et al., "Electrical and contractile remodeling during the first days of atrial fibrillation go hand in hand," Circulation, Vol. 107, pp. 1433-1439. (2003)		
CU1	Shiroshita-Takeshita et al., "Atrial fibrillation: basic mechanisms, remodeling and triggers," J. Interv. Card. Electrophysiol, Vol. 13, pp. 181-193. (2005)		
CV1	Shtifman, et al., "Interdomain interactions within ryanodine receptors regulate Ca ²⁺ spark frequency in skeletal muscle," J. Gen. Physiol., Vol. 119, pp. 15-31 (2002)		
CW1	Special Report "Preliminary Report: Effect of Encainide and Flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction," The New England Jour. of Med., Vol 321, No 6, pp. 406-412. (1989)		
CX1	Stevenson, W.G. et al., "Sudden death prevention in patients with advanced ventricular dysfunction," Circulation, Vol. 88, pp. 2953-2961. 1993		
CY1	Swan, et al., "Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations," J. of Card. Electrophysiology, Vol. 16, No. 2, pp. 162-6, (2005)		
CZ1	Szabo et al. "Synthesis and Transformations of 4,5-Dihydro-1,4-benzothiazepin-3(2H)-one Derivatives 1,2," Chemische Berichte., Vol. 119, No. 9, pp. 2904-2913. (1986).		
CA2	Szabo, Janos et al., "Synthesis and Spectroscopic Investigations of 1,4-benzothiazepine derivatives." Can. J. Chem, Vol. 65, pp. 175-181. (1987).		
CB2	Tester, et al., "Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing," Heart Rhythm. Vol. 2, pp. 507-17 (2005)		
CC2	Tester, et al., "Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: a molecular autopsy of 40 medical examiner/coroner's cases," May Clin. Proc., Vol. 79, pp. 1380-4 (2004)		
CD2	Timmerman, et al., "The ryanodine receptor from canine heart sarcoplasmic reticulum is associated with a novel FK-506 binding protein," Biochem. Biophys. Res. Commun., Vol. 198, pp. 701-6 (1994)		
CE2	Tipton, et al., "My child just fainted: no big deal or sudden-death warning?" Emerg. Med. Serv., Vol. 33, pp. 41-5 (2004)		
CF2	Wang, et al., "Retinoic acid stimulates annexin-mediated growth plate chondrocyte mineralization," J. Cell Biol., Vol. 157, pp. 1061-9 (2002)		
CG2	Wang, W., et al., "Annexin-mediated Ca ²⁺ influx regulates growth plate chondrocyte maturation and apoptosis," J. Biol Chem, Vol. 278, pp. 3762-9 (2003)		
CH2	Ward, et al., "Defects in ryanodine receptor calcium release in skeletal muscle from post-myocardial infarct rats," Faseb J., Vol. 17, pp. 1517-9 (2003)		
CI2	Wehrens, et al., "Altered function and regulation of cardiac ryanodine receptors in cardiac disease," Trends Biochem. Sci., Vol. 28, pp. 671-8 (2003)		
CJ2	Wehrens, et al., "Myocardial disease in failing hearts: defective excitation-contraction coupling," Cold Spring Harb. Symp. Quant. Biol., Vol. 67, pp. 533-41 (2002)		
CK2	Wilde et al., "Ion Channels, the QT interval, and arrhythmias," Pacing Clin Electrophysiol, Vol. 20, pp. 2048-2051. 1997		
CL2	Yamamoto, et al., "Ca ²⁺ -dependent dual function of peptide C. The peptide corresponding to the Glu724-Pro760 region (the so-called determinant of excitation-contraction coupling) of the dihydropyridine receptor alpha 1 subunit II-III loop," J. Biol. Chem., Vol. 277, pp. 993-1001 (2002)		
CM2	Yamamoto, et al., "Peptide probe study of the critical regulatory domain of the cardiac ryanodine receptor," Biochem. Biophys. Res. Commun., Vol. 291, pp. 1102-8 (2002)		

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/608,723-Conf. #6915
				Filing Date	June 26, 2003
				First Named Inventor	Andrew R. MARKS
				Art Unit	1646
				Examiner Name	R. Li
Sheet	9	of	9	Attorney Docket Number	0019240.00594US1

	CN2	Yamamoto, et al., "Spectroscopic monitoring of local conformational changes during the intramolecular domain-domain interaction of the ryanodine receptor," Biochemistry, Vol. 41, pp. 1492-501 (2002)	
	CO2	Yamamoto, et al., "T-tubule depolarization-induced local events in the ryanodine receptor, as monitored with the fluorescent conformational probe incorporated by mediation of peptide A," J. Biol. Chem. Vol. 277, pp. 984-92 (2002)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Application No. (if known): 10/608,723

Attorney Docket No.: 0019240.00594US1

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 901256293 US in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on 3/5/07
Date

Signature

Jane M. Love, Ph.D.

Typed or printed name of person signing Certificate

42,812

Registration Number, if applicable

(212) 230-8800

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (279 References) (9 pages)
Supplemental Information Disclosure Statement (2 pages)
Fee Transmittal (1 page)
Transmittal (1 page)
Postcard